Clinical Studies and Case Reports

On this site you will find clinical studies with cannabis or single cannabinoids in different diseases and case reports on the use of cannabis by patients.
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.




[Back to Overview]  [IACM Homepage]

TitleExperience with the synthetic cannabinoid nabilone in chronic noncancer pain.
Author(s)Berlach DM, Shir Y, Ware MA.
Journal, Volume, IssuePain Med. 2006 Jan-Feb;7(1):25-9.
Major outcome(s)9 patients reported reduced pain intensity
IndicationPainAbstract
MedicationNabilone

Chronic noncancer pain includes a heterogeneous group of disorders and is often refractory to treatment. Cannabis products have historically been used for chronic pain and are attracting renewed pharmaceutical interest. Nabilone is a synthetic cannabinoid licensed in Canada for the treatment of severe nausea and vomiting associated with cancer chemotherapy. We have used nabilone off-label for the treatment of chronic noncancer pain since 1999. In this article, we review our clinical experience of 20 adult patients with chronic noncancer pain who had been treated with nabilone and followed up for an average of 1.5 years. Prior to nabilone therapy, patients had used a wide range of therapies, including 11 who had used cannabis. Fifteen patients reported subjective overall improvement with nabilone, and nine reported reduced pain intensity. Beneficial effects on sleep and nausea were the main reasons for continuing use. Intolerable side effects were experienced in three patients (palpitations, urinary retention, dry mouth). Nabilone may be a useful addition to pain management and should be further evaluated in randomized controlled trials.

Route(s)Oral
Dose(s)
Duration (days)
Participants20 patients with non-cancer pain
DesignOpen study
Type of publicationMedical journal
Address of author(s)McGill University Medical School, McGill University Health Center, Montreal, Quebec, Canada.
Full text

[Back to Overview]  [IACM Homepage]


up